Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 7;14(7):e00578. doi: 10.14309/ctg.0000000000000578

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 2. — Correlation between IL-23 pathway transcripts and changes in disease activity scores. (a) Pearson correlation coefficients for the differential expression of mirikizumab-regulated genes at week 12 with change over the same period in modified Mayo score (green), RHI (red), and UCEIS (gray). Genes that are identified by the MetaCore database (Clarivate Analytics, Philadelphia, PA) as being upregulated by IL-23 are labeled. (b) Heat map of Pearson correlation coefficients (Rho) for the differential expression of each gene identified above. Fold change values for each gene in the 200 mg mirikizumab dose group after normalization with the change in the placebo group are labeled on the vertical axis. (c) Correlation between changes in mirikizumab-regulated genes and changes in disease activity scores. Pearson correlation coefficients for the differential expression of mirikizumab-regulated genes at week 12 with change over the same period in modified Mayo score (green), RHI (red), and UCEIS (gray). Genes with a differential expression of ≥2-fold in the 200 mg mirikizumab dose group after normalization with change in the placebo group are labeled. All labeled genes that were positively correlated with changes in disease activity scores decreased between baseline and week 12, and those that were negatively correlated with changes in disease activity scores increased in expression over that period. RHI, Robarts Histopathology Index; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.